Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1951 3
1952 1
1955 1
1956 1
1957 1
1963 2
1965 2
1966 2
1967 5
1968 1
1969 1
1971 4
1972 2
1973 2
1974 2
1975 9
1976 16
1977 4
1978 5
1979 5
1980 8
1981 5
1982 4
1983 6
1984 6
1985 7
1986 6
1987 6
1988 6
1989 4
1990 6
1991 1
1992 7
1993 5
1994 12
1995 4
1996 6
1997 4
1998 2
1999 1
2000 3
2001 8
2002 3
2003 1
2004 5
2005 2
2006 2
2007 4
2008 3
2009 4
2010 2
2011 3
2012 2
2013 2
2014 4
2015 4
2016 8
2017 11
2018 9
2019 7
2020 11
2021 13
2022 13
2023 17
2024 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders.
Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Coban Akdemir ZH, Erichsen HC, Forbes LR, Gu S, Yuan B, Jhangiani SN, Muzny DM, Rødningen OK, Sheng Y, Nicholas SK, Noroski LM, Seeborg FO, Davis CM, Canter DL, Mace EM, Vece TJ, Allen CE, Abhyankar HA, Boone PM, Beck CR, Wiszniewski W, Fevang B, Aukrust P, Tjønnfjord GE, Gedde-Dahl T, Hjorth-Hansen H, Dybedal I, Nordøy I, Jørgensen SF, Abrahamsen TG, Øverland T, Bechensteen AG, Skogen V, Osnes LTN, Kulseth MA, Prescott TE, Rustad CF, Heimdal KR, Belmont JW, Rider NL, Chinen J, Cao TN, Smith EA, Caldirola MS, Bezrodnik L, Lugo Reyes SO, Espinosa Rosales FJ, Guerrero-Cursaru ND, Pedroza LA, Poli CM, Franco JL, Trujillo Vargas CM, Aldave Becerra JC, Wright N, Issekutz TB, Issekutz AC, Abbott J, Caldwell JW, Bayer DK, Chan AY, Aiuti A, Cancrini C, Holmberg E, West C, Burstedt M, Karaca E, Yesil G, Artac H, Bayram Y, Atik MM, Eldomery MK, Ehlayel MS, Jolles S, Flatø B, Bertuch AA, Hanson IC, Zhang VW, Wong LJ, Hu J, Walkiewicz M, Yang Y, Eng CM, Boerwinkle E, Gibbs RA, Shearer WT, Lyle R, Orange JS, Lupski JR. Stray-Pedersen A, et al. Among authors: gedde dahl t. J Allergy Clin Immunol. 2017 Jan;139(1):232-245. doi: 10.1016/j.jaci.2016.05.042. Epub 2016 Jul 16. J Allergy Clin Immunol. 2017. PMID: 27577878 Free PMC article.
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, Yoshizato T, Rustad EH, Nielsen MM, Bollineni RC, Tran TT, Delic-Sarac M, Gjerdingen TJ, Douvlataniotis K, Laos M, Ali M, Hillen A, Mazzi S, Chin DWL, Mehta A, Holm JS, Bentzen AK, Bill M, Griffioen M, Gedde-Dahl T, Lehmann S, Jacobsen SEW, Woll PS, Olweus J. Giannakopoulou E, et al. Among authors: gedde dahl t. Nat Cancer. 2023 Oct;4(10):1474-1490. doi: 10.1038/s43018-023-00642-8. Epub 2023 Oct 2. Nat Cancer. 2023. PMID: 37783807 Free PMC article.
[Chronic graft-versus-host disease].
Rørvik SD, Abrahamsen IW, Myhre AE, Vo CD, Ødegaard EM, Bruserud Ø, Gedde-Dahl T, Tvedt THA. Rørvik SD, et al. Among authors: gedde dahl t. Tidsskr Nor Laegeforen. 2023 Mar 13;143(4). doi: 10.4045/tidsskr.22.0525. Print 2023 Mar 14. Tidsskr Nor Laegeforen. 2023. PMID: 36919292 Free article. Norwegian.
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, Gedde-Dahl T, Blau IW, Schroeder T, Salmenniemi U, Kulagin A, Peffault de Latour R, Mielke S, Zeiser R, Moiseev I, Schoemans H, Koenecke C, Peric Z. Penack O, et al. Among authors: gedde dahl t. Leukemia. 2024 May;38(5):1156-1163. doi: 10.1038/s41375-024-02225-7. Epub 2024 Mar 27. Leukemia. 2024. PMID: 38538862 Free PMC article.
Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease.
Divito SJ, Aasebø AT, Matos TR, Hsieh PC, Collin M, Elco CP, O'Malley JT, Bækkevold ES, Reims H, Gedde-Dahl T, Hagerstrom M, Hilaire J, Lian JW, Milford EL, Pinkus GS, Ho VT, Soiffer RJ, Kim HT, Mihm MC, Ritz J, Guleria I, Cutler CS, Clark RA, Jahnsen FL, Kupper TS. Divito SJ, et al. Among authors: gedde dahl t. J Clin Invest. 2020 Sep 1;130(9):4624-4636. doi: 10.1172/JCI129965. J Clin Invest. 2020. PMID: 32516138 Free PMC article. Clinical Trial.
328 results